Hirotaka Miyashita

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/2602207/publications.pdf

Version: 2024-02-01

1163117 839539 24 465 8 18 citations g-index h-index papers 29 29 29 1125 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Bone-modifying agents for bone loss in patients with prostate cancer receiving androgen deprivation therapy; insights from a network meta-analysis. Supportive Care in Cancer, 2022, 30, 855-863.	2.2	2
2	Metabolic Bone Disease and Osteoporosis. , 2022, , 119-146.		0
3	Incidence of hepatotoxicity associated with addition of immune checkpoint blockade to systemic solid tumor therapy: a meta-analysis of phase 3 randomized controlled trials. Cancer Immunology, Immunotherapy, 2022, 71, 2837-2848.	4.2	5
4	First-line therapy for elderly patients with advanced renal cell carcinoma (aRCC): A systemic review and network meta-analysis Journal of Clinical Oncology, 2022, 40, 4532-4532.	1.6	0
5	Network meta-analysis of anticoagulation strategies for venous thromboembolism in patients with cancer. Journal of Thrombosis and Thrombolysis, 2021, 51, 102-111.	2.1	8
6	Risk Factors for Mortality in Patients with COVID-19 in New York City. Journal of General Internal Medicine, 2021, 36, 17-26.	2.6	175
7	Risk factors of skeletal-related events in patients with bone metastasis from non-small cell lung cancer undergoing treatment with zoledronate—a post hoc analysis of a randomized clinical trial. Supportive Care in Cancer, 2021, 29, 1629-1633.	2.2	7
8	Cardiovascular and renal outcomes with SGLT-2 inhibitors versus GLP-1 receptor agonists in patients with type 2 diabetes mellitus and chronic kidney disease: a systematic review and network meta-analysis. Cardiovascular Diabetology, 2021, 20, 14.	6.8	74
9	Incidence of hepatitis associated with addition of immune checkpoint blockade to conventional solid tumor therapy: A meta-analysis of phase 3 randomized clinical trials Journal of Clinical Oncology, 2021, 39, 2645-2645.	1.6	1
10	Is there a racial disparity in coronavirus disease 2019 patients with chronic kidney disease? An experience in New York City. International Journal of Clinical Practice, 2021, 75, e14261.	1.7	0
11	Risk factors of skeletal-related events in patients with bone metastatic castration-resistant prostate cancer undergoing treatment with zoledronate. Supportive Care in Cancer, 2021, 30, 981.	2.2	2
12	Effect of Exposure to Agent Orange on the Risk of Monoclonal Gammopathy and Subsequent Transformation to Multiple Myeloma: A Single-Center Experience From the Veterans Affairs Hospital, Detroit. Clinical Lymphoma, Myeloma and Leukemia, 2020, 20, 305-311.	0.4	9
13	Neoâ€adjuvant therapy for tripleâ€negative breast cancer: Insights from a network metaâ€analysis. Breast Journal, 2020, 26, 1717-1728.	1.0	2
14	The Association Between Hemoglobin Upswing in the Reference Range and Sleep Apnea Syndrome. Sleep and Vigilance, 2020, 4, 205-212.	0.8	1
15	First-in-class humanized FSH blocking antibody targets bone and fat. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 28971-28979.	7.1	35
16	Incidence and Risk of Colitis With Programmed Death 1 Versus Programmed Death Ligand 1 Inhibitors for the Treatment of Cancer. Journal of Immunotherapy, 2020, 43, 291-298.	2.4	7
17	Patients with chronic kidney disease have a poorer prognosis of coronavirus disease 2019 (COVID-19): an experience in New York City. International Urology and Nephrology, 2020, 52, 1405-1406.	1.4	35
18	Risk factors for skeletal-related events in patients with bone metastasis from breast cancer undergoing treatment with zoledronate. Breast Cancer Research and Treatment, 2020, 182, 381-388.	2.5	7

#	Article	IF	CITATIONS
19	A Case of Dual Positive Glomerulonephritis With Plasma Cell Dyscrasia. American Journal of Medicine, 2020, 133, e436-e437.	1.5	O
20	Value of leukocytosis and elevated C-reactive protein in predicting severe coronavirus 2019 (COVID-19): A systematic review and meta-analysis. Clinica Chimica Acta, 2020, 509, 235-243.	1.1	66
21	Repurposing erectile dysfunction drugs tadalafil and vardenafil to increase bone mass. Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 14386-14394.	7.1	16
22	Parathyroid Gland Diseases., 2020,, 65-74.		0
23	Bone modifying agents for bone loss in patients with aromatase inhibitor as adjuvant treatment for breast cancer; insights from a network meta-analysis. Breast Cancer Research and Treatment, 2020, 181, 279-289.	2.5	11
24	Association Between Electroencephalogram-Derived Sleep Measures and the Change of Emotional Status Analyzed Using Voice Patterns: Observational Pilot Study. JMIR Formative Research, 2020, 4, e16880.	1.4	2